The study was aimed at analyzing the pharmacokinetics of sulphadiazine (SDZ) and trimethoprim (TMP) in geriatric patients and was carried out in two stages. The first stage compared 11 geriatric patients (68–89 years old) and 9 healthy volunteers (21–34 years old). Serum concentration and urine elimination were determined on day 4 after 12-hourly administration of 1 tablet of co-trimazine containing 410 mg sulphadiazine (SDZ) plus 90 mg trimethoprim (TMP). The mean serum concentrations of SDZ were significantly higher in the older subjects than in the volunteers after 1, 8 and 12 h (p < 0.05, 0.01, 0.01), but were not differentiable after 2 or 4 h. For TMP, the serum levels were higher (p < 0.05) in the patients only after 8 h. The amounts collected in urine were higher in the normal volunteers for SDZ during the intervals 0–2 h (p < 0.05), 2–4 h (p < 0.01), and 4–8 h (p < 0.01), but not for 8–12 h. The 12-hour recovery was 69% SDZ + acetyl-SDZ recovered in the patients compared to 66.0% in the volunteers. Indistinguishable amounts of TMP were recovered during each interval in the two groups of subjects, 59.2% in the patients compared to 70.0% in the volunteers. The second stage of the study comprised 9 geriatric patients of mean age 83.6 years and creatinine clearance 59.2 ml/min who were followed for 11 days. A steady increase in serum levels was observed. The mean peak serum concentration for SDZ was 16.7 ± 4.2 mg/l after the first dose and 44.7 ± 11.3 mg/l on day 10. For acetyl-SDZ, the respective concentrations were 2.1 ± 0.9 and 7.1 ± 3.1 mg/l. TMP rose from 0.79 ± 0.19 mg/l on the first day to 2.8 ± 1.3 mg/l on day 10. Parallel increases in urine elimination of SDZ, acetyl-SDZ and TMP were observed over the 11 days. After the first dose, the 12-hour urine elimination of SDZ corresponded to 16.2% of the dose, that of acetyl-SDZ to 7.5% and of TMP 21.5%. After the final dose, the respective 48-hour values were 103.2, 51.2 and 115%. The t½ was 16.2 ± 5.6 h for SDZ, 25.5 ± 12.3 h for acetyl-SDZ, and 14.0 ± 6.0 h for TMP.

Keywords:
Pharmacokinetics, Geriatrics sulphadiazine, Trimethoprim
This content is only available via PDF.
© 1986 S. Karger AG, Basel
1986
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.